<DOC>
	<DOCNO>NCT01672736</DOCNO>
	<brief_summary>This multi-center , open-label , non-randomized study . Patients receive ASP7487 ( OSI-906 ) combination bortezomib dexamethasone . Phase 1 involves dose escalation combination , whereas Phase 2 involve expansion ASP7487 ( OSI-906 ) combine bortezomib dexamethasone MTD establish ORR . This trial accrue patient relapse relapsed/refractory MM - disease state bortezomib approve treat FDA Health Canada . The combination ASP7487 ( OSI-906 ) bortezomib support pre-clinical work MM combination IGF1-R inhibitor enhance anti-tumor activity bortezomib .</brief_summary>
	<brief_title>A Trial ASP7487 ( OSI-906 ) Combination With Bortezomib Treatment Relapsed Multiple Myeloma</brief_title>
	<detailed_description>The Phase 1 portion study determine MTD DLTs bortezomib administer day 1 , 4 , 8 11 21-day cycle combine ASP7487 ( OSI-906 ) dose twice daily orally continuously . The combination ASP7487 ( OSI-906 ) bortezomib previously test . The active agent bortezomib use Cycle 1 - 8 recommend treatment dose 1.3 mg/m2 day 1 , 4 , 8 11 Cycles 9+ day 1 , 8 , 15 22 5-week cycle ASP7487 ( OSI-906 ) dose escalate form 75 mg 150mg utilizing 3+3 design</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion Criteria 1 . Males female , age 18 year old . 2 . Relapsed relapse/refractory MM least 1 prior line therapy phase 1 1 5 prior line therapy phase 2 . 3 . Patients measurable disease define least one follow 1 . Serum Mprotein ≥ 0.5 g/dl ( ≥ 5 g/l ) 2 . Urine Mprotein ≥ 200 mg/24 h 3 . Serum free light chain ( FLC ) assay : Involved FLC level ≥ 10 mg/dl ( ≥ 100 mg/l ) abnormal serum free light chain ratio ( &lt; 0.26 &gt; 1.65 ) 4 . Biopsy proven plasmacytoma . Prior biopsy acceptable . 5 . If serum protein electrophoresis unreliable routine Mprotein measurement , quantitative immunoglobulin level nephrolometry turbidometry follow . 4 . ECOG ≤ 2 OR Karnofsky ≥ 60 % . 5 . Predose mean QTc≤ 450 msec QTcF ≤ 450 msec . 6 . Negative pregnancy test Females childbearing potential . 7 . Voluntary , write informed consent . 8 . Ability understand purpose risk study . 9 . Must able take retain oral medication . 10 . Inclusion Clinical Laboratories Criteria 1 . Absolute neutrophil count ( ANC ) &gt; 1,000 cells/dL ( 1.0 x 109/L ) 2 . Platelet count &gt; 50,000 cells/dL ( 50 x 109/L ) 3 . Hemoglobin ≥ 8.0 g/dL ( 4.96 mmol/L ) 4 . Serum AST ALT ≤ 1.2 x ULN 5 . Total bilirubin within normal limit 6 . Creatinine clearance ≥ 30 mL/min 7 . Serum creatinine ≤ 1.5 x ULN 8 . Serum calcium ( ionize correct albumin ) ≥ 2.0 mmol/L ( 8.0 mg/dL 1.0 mmol/L ionized calcium ) ≤ 1.2 x ULN . 9 . Serum potassium , magnesium within normal limit 10 . HgbA1c ≤ 7 % 11 . Troponin I T within normal limit 12 . BNP NTproBNP within normal limit 13 . Fasting glucose ≤126 mg/dL ( 7.0 mmol/L ) . 11 . Resolution prior treatment associated toxicity ≤ grade 1 Exclusion Criteria 1 . Bortezomib refractory patient permit Phase 2 part study . 2 . Diagnosed treat another malignancy within 3 year enrollment , except completely resect basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . 3 . Patient receive investigational drug chemotherapy within 21 day approve antimyeloma therapy within 14 day . 4 . History ( within last 6 month ) significant cardiovascular disease . 5 . Mean QTcF interval &gt; 450 msec screening . 6 . Prior autologous , peripheral stem cell transplant within 12 week first dose study drug . 7 . Daily requirement corticosteroid ( except inhalation corticosteroid ) . 8 . Patients evidence mucosal internal bleeding and/or platelet transfusion refractory ( i.e. , unable maintain platelet count ≥ 50,000 cells/dL ) . 9 . Known active infection require parenteral oral antiinfective treatment . 10 . Serious psychiatric illness , active alcoholism , drug addiction may hinder confuse followup evaluation . 11 . Use medical condition , Investigator 's opinion , would impose excessive risk patient . 12 . Patient hypersensitivity component study drug . 13 . Known HIV active hepatitis B C viral infection . 14 . Diabetes mellitus currently require insulin insulinotropic therapy prior history steroid induce diabetes . 15 . History cerebrovascular accident ( CVA ) within 6 month prior registration stable . 16 . Prior therapy IGF1R inhibitor . 17 . Use drug risk cause QT interval prolongation and/or know risk cause Torsades de Pointes ( TdP ) 14 day recommend 5 halflife . 18 . Use strong/moderate CYP1A2 inhibitor . 19 . Gastrointestinal abnormality could affect absorption study drug . 20 . Peripheral neuropathy ≥ grade 2 . 21 . Significant liver disease metastatic disease liver 22 . History amyloid , plasma cell leukemia CNS involvement . 23 . Radiation therapy major surgical procedure within 4 week first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Relapsed relapse/refractory Multiple Myeloma</keyword>
</DOC>